
    
      The purpose of the study is to see how well patients with relapsed or refractory lymphoma
      respond to treatment with Gemcitabine and Irinotecan. Patients on this study take part
      because they have relapsed or refractory lymphoma. Additionally, the study will assess
      treatment-related side effects and time until disease progression or recurrence.
    
  